Erasca (NASDAQ:ERAS) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Erasca (NASDAQ:ERAS) posted its quarterly earnings data on Wednesday. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03), FiscalAI reports.

Erasca Price Performance

ERAS opened at $17.86 on Friday. Erasca has a one year low of $1.33 and a one year high of $24.28. The business has a 50 day simple moving average of $17.18 and a two-hundred day simple moving average of $15.00. The firm has a market capitalization of $6.25 billion, a price-to-earnings ratio of -18.80 and a beta of 0.66.

Trending Headlines about Erasca

Here are the key news stories impacting Erasca this week:

• Positive Sentiment: HC Wainwright retained its Buy rating and $22.00 price objective for Erasca. With shares opening at $17.86, the target indicates potential upside if the company’s pipeline and clinical-development prospects support the analyst’s valuation. HC Wainwright Increases Erasca Price Target to $22.00
• Neutral Sentiment: HC Wainwright’s revised FY2026 EPS forecast of a $0.51 loss is slightly better than the current consensus estimate of a $0.54 loss, although Erasca remains unprofitable and analysts still expect losses in every forecast period.
• Negative Sentiment: The analyst lowered projected EPS for Q3 2026 to a $0.14 loss from $0.13, and Q4 2026 to a $0.15 loss from $0.14. Full-year estimates were also reduced for FY2027 to a $0.58 loss, FY2028 to $0.61, FY2029 to $0.70, and FY2030 to $0.54. The largest revisions were for FY2029 and FY2030, suggesting weaker expected profitability or higher operating costs over the longer term.

Analyst Upgrades and Downgrades

ERAS has been the subject of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research note on Thursday, June 11th. Bank of America boosted their price target on shares of Erasca from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 14th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Erasca in a research note on Tuesday, July 14th. Guggenheim boosted their target price on Erasca from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Wall Street Zen cut Erasca from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Erasca has a consensus rating of “Moderate Buy” and an average price target of $21.91.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Vivo Capital LLC boosted its stake in shares of Erasca by 37.2% during the 3rd quarter. Vivo Capital LLC now owns 9,273,428 shares of the company’s stock valued at $20,216,000 after purchasing an additional 2,516,672 shares in the last quarter. State Street Corp lifted its holdings in Erasca by 53.2% in the fourth quarter. State Street Corp now owns 6,174,642 shares of the company’s stock worth $22,970,000 after buying an additional 2,145,386 shares during the period. Paradigm Biocapital Advisors LP boosted its position in Erasca by 13.9% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 13,560,017 shares of the company’s stock valued at $29,561,000 after acquiring an additional 1,652,835 shares in the last quarter. VR Adviser LLC grew its holdings in shares of Erasca by 10.1% during the 2nd quarter. VR Adviser LLC now owns 17,857,083 shares of the company’s stock worth $22,678,000 after acquiring an additional 1,640,867 shares during the period. Finally, ExodusPoint Capital Management LP bought a new position in shares of Erasca in the 4th quarter worth approximately $5,546,000. 67.78% of the stock is currently owned by institutional investors.

Erasca Company Profile

Erasca, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of precision medicines for patients with cancer. The company focuses on small molecule therapeutics that target critical signaling pathways involved in tumor growth and survival, with a primary emphasis on inhibitors of the MAPK pathway. Erasca’s approach is designed to deliver oral, targeted therapies that address both oncogene?driven and immuno?oncology indications, aiming to improve outcomes for patients with unmet medical needs.

Erasca’s pipeline comprises multiple development candidates, including small molecule inhibitors engineered to disrupt key nodes in cancer cell signaling.